Dymara-Konopka Weronika, Laskowska Marzena, Błażewicz Anna
Department of Obstetrics and Perinatology, Medical University of Lublin, Poland, 20-950 Lublin, Jaczewskiego 8, Poland.
Chemistry, Department of Analytical Chemistry, Medical University of Lublin, Poland, Al. Racławickie 1, Lublin, Poland.
Curr Pharm Biotechnol. 2018;19(10):797-815. doi: 10.2174/1389201019666180925115559.
Preeclampsia is one of the most serious pregnancy - specific medical conditions affecting 3- 6% of all gestations. It remains a leading cause of maternal and fetal morbidity and mortality. The aetiology of preeclampsia is not fully elucidated yet, although a huge progress has been made in its understanding within the last decade. Numerous studies have provided compelling evidence that an excess of some antiangiogenic molecules released by the placenta to maternal circulation, in particular soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng) and decreased levels of proangiogenic substances like placental growth factor (PlGF) and vascular endothelial growth factor A (VEGF-A) play a key role in the pathogenesis of preeclampsia. In this review, we report recent knowledge about possible predictive, diagnostic and therapeutic roles of these pro- and antiangiogenic biomarkers as well as analyzed the background of their use in these fields. Discoveries in the area of circulating factors of angiogenesis are exciting and give promising perspectives for future clinical management of preeclampsia. Currently, it can be difficult, especially in developing countries due to high cost of such studies.
子痫前期是最严重的特定于妊娠的医学病症之一，影响着3%至6%的所有妊娠。它仍然是孕产妇和胎儿发病及死亡的主要原因。尽管在过去十年中对子痫前期的认识取得了巨大进展，但其病因尚未完全阐明。大量研究提供了令人信服的证据，表明胎盘释放到母体循环中的一些抗血管生成分子过多，特别是可溶性fms样酪氨酸激酶1（sFlt-1）和可溶性内皮糖蛋白（sEng），以及胎盘生长因子（PlGF）和血管内皮生长因子A（VEGF-A）等促血管生成物质水平降低，在子痫前期的发病机制中起关键作用。在本综述中，我们报告了关于这些促血管生成和抗血管生成生物标志物可能的预测、诊断和治疗作用的最新知识，并分析了它们在这些领域应用的背景。血管生成循环因子领域的发现令人兴奋，并为子痫前期的未来临床管理提供了有希望的前景。目前，这可能很困难，尤其是在发展中国家，因为此类研究成本高昂。
